Oyster Point Pharma EBITDA 2011-2026 | OYST

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Oyster Point Pharma

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-96.5 M	-70.5 M	-47.3 M	-16.5 M	-5.64 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-5.64 M	-96.5 M	-47.3 M

Quarterly EBITDA Oyster Point Pharma

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-33.7 M	-43.2 M	-42.1 M	-	-16.7 M	-22 M	-18.9 M	-22.2 M	-16.3 M	-15.5 M	-16.9 M	-20.2 M	-11.9 M	-11.2 M	-4.01 M	-4.05 M	-6.69 M	-3 M	-3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-3 M	-43.2 M	-17.3 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	-199 M	$ 3.44	-4.32 %	$ 1.03 B	Canada
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Aptorum Group Limited APM	1.19 M	$ 0.79	-1.15 %	$ 4.31 M	China
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
ADMA Biologics ADMA	199 M	$ 15.36	-2.17 %	$ 3.66 B	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Apellis Pharmaceuticals APLS	57 M	$ 20.28	0.65 %	$ 2.56 B	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Autolus Therapeutics plc AUTL	-234 M	$ 1.51	1.35 %	$ 385 M	Britain
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Anika Therapeutics ANIK	-81.2 M	$ 14.05	-1.44 %	$ 206 M	USA
ANI Pharmaceuticals ANIP	68.3 M	$ 74.36	-1.64 %	$ 1.44 B	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Athersys ATHX	-85.6 M	-	3.77 %	$ 22.4 M	USA
AVEO Pharmaceuticals AVEO	-49.5 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-166 M	$ 162.43	0.6 %	$ 8.08 B	USA
BioCryst Pharmaceuticals BCRX	-1.3 M	$ 8.49	-0.18 %	$ 1.75 B	USA
BridgeBio Pharma BBIO	-518 M	$ 65.66	-0.78 %	$ 12.6 B	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Brainstorm Cell Therapeutics BCLI	-11.5 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
Bellicum Pharmaceuticals BLCM	-27 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-89 M	-	-7.31 %	$ 87 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
BioLineRx Ltd. BLRX	-24.8 M	$ 2.69	-0.74 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	489 M	$ 61.3	1.21 %	$ 11.8 B	USA
Burford Capital Limited BUR	242 M	$ 7.79	-5.75 %	$ 1.28 B	Britain
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
Codexis CDXS	-53.6 M	$ 1.23	-2.38 %	$ 90.3 M	USA
Cabaletta Bio CABA	-73.2 M	$ 3.18	-0.16 %	$ 3.71 M	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Clovis Oncology CLVS	-217 M	-	-7.23 %	$ 13 M	USA